Latest From Hannah Daniel
Bragg Live says its survey highlights misconceptions consumers have concerning health benefits and efficacy of different delivery formats of apple cider vinegar.
"Many of the problems facing [the FDA] can be solved through strong leadership rather than more money,” says Rep. Andy Harris during Appropriations subcommittee hearing, Committee Chairwoman Rosa DeLauro continues her criticism of FDA's regulation of industries under its oversight, saying a "structural problem" caused infant formula shortage.
Over The Counter 24 May 2022: US OTC Monograph Reform And A 'Faster Moving FDA’ With CHPA’s Barbara Kochanowski and David Spangler
In this episode, HBW Insight speaks to Barbara Kochanowski and David Spangler of the US Consumer Healthcare Products Association about OTC monograph reform. The OTC monograph program was reimagined as a part of the 2020 CARES act passed in the early stages of the pandemic. While the changes were designed to streamline and modernize the program, results have been slow with the FDA's attention focused on tackling COVID-19. But as the agency hires more staff, Spangler says he expects to see a "faster moving FDA" in the next three years. Spangler and Kochanowski also discuss the efficacy of the monograph reforms and how CHPA has helped educate its members about the changes.
Patricia Hansen, CFSAN’s Office of Nutrition and Food Labeling deputy director and John Verbeten, deputy director for Import Operations Enforcement laid out the FDA's new enforcement guidance, and urged businesses with available formula to wait for approval before distributing formula in the US.
Before Agriculture/FDA subcommittee about FY2023 budget, Commissioner Robert Califf says FDA needs more resources to address unlisted fragrances in menstrual products and doesn’t have good regulatory options for hemp and kratom. His formula emergency comments leave members frustrated.
Study of 1,061 subjects showed oral CBD has robust safety profile, addressing FDA’s safety concerns and providing evidence to convince agency to take action on CBD regulation, say trade groups.